Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
about
LHRH agonists for adjuvant therapy of early breast cancer in premenopausal womenSignificance of Ovarian Function Suppression in Endocrine Therapy for Breast Cancer in Pre-Menopausal WomenCurrent medical treatment of estrogen receptor-positive breast cancerAdjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineMenopausal symptoms in young survivors of breast cancer: a growing problem without an ideal solutionConcordance between decision analysis and matching systematic review of randomized controlled trials in assessment of treatment comparisons: a systematic review.AGO Recommendations for Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2013.Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer - Chapter A: Surgery, Pathology and Prognostic Factors, Adjuvant and Neoadjuvant Therapy, Adjuvant Radiotherapy'An ounce of prevention is worth a pound of cure': the case for and against GnRH-agonist for fertility preservation.Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer.Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Status of adjuvant endocrine therapy for breast cancer.Emerging gonadotropin-releasing hormone agonists.Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two casesGnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines.Adjuvant Endocrine Therapy in Premenopausal PatientsLonger therapy, iatrogenic amenorrhea, and survival in early breast cancer.Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.Is Chemoendocrine Treatment without Alternative?Breast cancer in young women: special considerations in multidisciplinary care.Standard of care and controversies in the adjuvant endocrine treatment of hormone-responsive early breast cancer.Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectivesTamoxifen and ovarian function.Postoperative endocrine therapy for invasive breast cancer.Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage II/III Hormone Receptor-Positive Breast Cancer without Chemotherapy-Induced AmenorrheaAdjuvant ovarian suppression in premenopausal breast cancer.Pharmacoeconomic considerations in the treatment of breast cancer.Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trialsAll nodes lead to chemo...Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatmentTamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials.Prevention and Treatment of Bone Metastases in Breast CancerOvarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer.The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progreOophorectomy in breast cancer-controversies and current status.Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.High-risk early breast cancer in patients under 40 years of age: Improved clinical outcome with total estrogen blockade and tailored chemotherapy.
P2860
Q24240015-1C31F2D2-49AE-4295-877C-937DE8D62CD9Q26745464-CB0AA4DD-029C-4FDB-A882-A050464900EBQ26795751-F0FD4132-613E-442F-A6BC-63260840E801Q27002430-26879ADA-DE19-4DA5-9084-27E5346A8948Q27025094-CE9E0D95-7DCE-478B-87E8-AA8014BA0553Q27690842-41875164-10CC-46D5-A9E6-2AEC77FE586CQ30317579-0A91EFAE-F4BF-4678-A6BB-3EFF388FD14DQ30318610-50A38E23-B6EC-4D2B-91FC-B50137407E6FQ30360464-FC827BF3-FB9A-4E07-98C4-D47C3392BE94Q31046050-0A085364-7F47-4ADE-A0F0-14D170ECA75FQ33649441-E2AEDB21-3A4F-4C89-8764-0BCF25336495Q33698446-235BA52F-5E1C-4C45-A5B2-1CC1607E5CFEQ33739138-D3959F81-F88A-46EF-B632-B59D912CB133Q33796122-AC8B7B0A-4E04-4463-9E72-B17B491BC81AQ33967497-8D69239E-7C72-4217-B0F9-17DD31C4CF8CQ34066386-656426DD-8E19-4EFA-988C-222B1B6C41B1Q34096277-7EC2AA8C-A13A-4DEA-9FB2-37257C70BDCBQ34109991-BC1B9991-F7FE-4941-86C2-DA96E8CA97C0Q34245992-844188AF-0F01-47CA-B28F-40F7D3F18DA1Q34284263-3C041D51-97AA-494B-91BB-C2686D3F0712Q34306522-9EB2EB01-A9BA-4037-A576-84C378A0D156Q34403564-F3894F94-CA41-45C0-B52A-6E807085BA27Q34611626-97B3FCC8-D0E1-40CD-8150-AC7AC4657918Q34655579-566F4C81-8437-46A2-AD8C-7B0558BA14E5Q34774649-8B1EDA18-E8C2-41EC-AEDE-87E665D5F459Q34805784-44C03B19-A5F2-4752-88B7-749D4E045853Q34910095-CFB7CDBD-D756-4191-9E61-6F98629266F4Q34977189-CB12F7EB-86CC-4EEE-9043-4DF286C4E886Q35124558-32E43F06-570C-45F6-B37D-BB41FB0BCD8AQ35205385-160B477F-9482-4513-B19A-20590725A789Q35558130-D6F3DCFC-0CE0-4DC5-942A-56AC71F0B67EQ35584910-8CA21576-3C8F-428C-B65C-681D54BDCDE2Q35617340-E404AF6C-61C8-4B1D-A1F4-C4CAD9F651FEQ35673773-7D8003CF-A674-49A0-86B6-75AE94903330Q35750652-6F3AB72F-921B-461C-AD24-B4467379471BQ35920776-81189F03-D088-46E3-B1C8-CA7ADAFA3CA4Q36022957-41E5D832-40D7-453C-B722-BCC8282BD9B9Q36095798-02016DB4-7E8B-42CB-974D-AFA099FD7ECAQ36240949-C4D407E3-6C94-4C27-9AC2-975CA8FCDB10Q36244136-779AC540-C2BF-4BF2-94F0-6D6C065825DB
P2860
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Use of luteinising-hormone-rel ...... om randomised adjuvant trials.
@ast
Use of luteinising-hormone-rel ...... om randomised adjuvant trials.
@en
type
label
Use of luteinising-hormone-rel ...... om randomised adjuvant trials.
@ast
Use of luteinising-hormone-rel ...... om randomised adjuvant trials.
@en
prefLabel
Use of luteinising-hormone-rel ...... om randomised adjuvant trials.
@ast
Use of luteinising-hormone-rel ...... om randomised adjuvant trials.
@en
P2093
P1433
P1476
Use of luteinising-hormone-rel ...... om randomised adjuvant trials.
@en
P2093
L Ambroisine
LHRH-agonists in Early Breast Cancer Overview group
M Kaufmann
N Davidson
R Sainsbury
P304
P356
10.1016/S0140-6736(07)60778-8
P407
P577
2007-05-01T00:00:00Z